RT Journal Article SR Electronic T1 Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68Ga-N188 JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 12S OP 18S DO 10.2967/jnumed.123.266830 VO 65 IS Supplement 1 A1 Zhang, Jianhua A1 Duan, Xiaojiang A1 Chen, Xueqi A1 Zhang, Zhuochen A1 Sun, Hongwei A1 Shou, Jiayin A1 Zhao, Guangyu A1 Wang, Jianxin A1 Ma, Yongsu A1 Yang, Yinmo A1 Tian, Xiaodong A1 Shen, Qi A1 Yu, Wei A1 He, Zhisong A1 Fan, Yan A1 Yang, Xing YR 2024 UL http://jnm.snmjournals.org/content/65/Supplement_1/12S.abstract AB Nectin cell adhesion molecule 4 (nectin-4) is a transmembrane protein overexpressed on a variety of cancers and plays an important role in oncogenic and metastatic processes. The nectin-4–targeted antibody–drug conjugate enfortumab vedotin has been approved for treating locally advanced or metastatic urothelial cancer, but the efficacy in other types of cancer remains to be explored. The aim of this study was to evaluate the feasibility of nectin-4–targeted PET imaging with 68Ga-N188 as a noninvasive method to quantify membranous nectin-4 expression in multiple tumor types—an approach that may provide insight for patient stratification and treatment selection. Methods: Sixty-two patients with 16 types of cancer underwent head-to-head 68Ga-N188 and 18F-FDG PET/CT imaging for initial staging or detection of recurrence and metastases. Correlation between lesion SUVmax and nectin-4 expression determined by immunohistochemistry staining was analyzed in 36 of 62 patients. Results: The SUVmax of 68Ga-N188 had a positive correlation with membranous nectin-4 expression in the various tumor types tested (r = 0.458; P = 0.005), whereas no association was observed between the SUVmax and cytoplasmic nectin-4 expression. The detection rates for patient-based analysis of 68Ga-N188 and 18F-FDG PET/CT examinations were comparable (95.00% [57/60] vs. 93.33% [56/60]). In patients with pancreatic cancer, 68Ga-N188 exhibited a potential advantage for detecting residual or locally recurrent tumors; this advantage may assist in clinical decision-making. Conclusion: The correlation between nectin-4–targeted 68Ga-N188 PET imaging and membranous nectin-4 expression indicates the potential of 68Ga-N188 as an effective tool for selecting patients who may benefit from enfortumab vedotin treatment. The PET imaging results provided evidence to explore nectin-4–targeted therapy in a variety of tumors. 68Ga-N188 may improve the restaging of pancreatic cancer but requires further evaluation in a powered, prospective setting.